Key facts
- This page summarizes ASP Isotopes Inc.'s Form 3 filing for ENDRA Life Sciences Inc. (NDRA).
- 0 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 08 Oct 2026, 16:15.
ASP Isotopes Inc. - 01 Oct 2026 Form 3 Insider Report for ENDRA Life Sciences Inc. (NDRA)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- NDRA
- Reported as of
- 01 Oct 2026
- Net transaction value
- $0
- Reporting owner signature
- ASP Isotopes Inc., By: /s/ Donald G. Ainscow, Name: Donald G. Ainscow, Title: Executive Vice President, General Counsel and Secretary
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
ASP Isotopes Inc. filed Form 3 for ENDRA Life Sciences Inc. (NDRA) on 08 Oct 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (2)
CIK 0001921865
Primary reporting owner
ASP Isotopes Inc.
- Relationship
- 10%+ Owner
- Address
- 2200 ROSS AVENUE, SUITE 4575E, DALLAS
- Signature
- ASP Isotopes Inc., By: /s/ Donald G. Ainscow, Name: Donald G. Ainscow, Title: Executive Vice President, General Counsel and Secretary
- Signature date
- 08 Oct 2026
CIK 0002157843
LHE LNG Holdings LLC
- Relationship
- 10%+ Owner
- Address
- 2200 ROSS AVENUE, SUITE 4575E, DALLAS
- Signature
- LHE LNG Holdings LLC, By: /s/ Donald G. Ainscow, Title: Donald G. Ainscow, Executive Vice President, General Counsel and Secretary
- Signature date
- 08 Oct 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NDRA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 66,846
- Date
- 01 Oct 2026
- Ownership
- By LHE LNG Holdings LLC
- Footnotes
- F1, F2
NDRA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 66,846
- Date
- 01 Oct 2026
- Ownership
- By LHE LNG Holdings LLC
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NDRA
holding
Derivative
Pre-Funded Warrants
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Oct 2026
- Ownership
- By LHE LNG Holdings LLC
- Underlying class
- Common Stock
- Underlying amount
- 511,541
- Exercise price
- $0.000100
- Footnotes
- F2, F3
NDRA
holding
Derivative
Pre-Funded Warrants
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Oct 2026
- Ownership
- By LHE LNG Holdings LLC
- Underlying class
- Common Stock
- Underlying amount
- 511,541
- Exercise price
- $0.000100
- Footnotes
- F2, F3
NDRA
holding
Derivative
Warrants
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Oct 2026
- Ownership
- By LHE LNG Holdings LLC
- Underlying class
- Common Stock
- Underlying amount
- 1,156,774
- Exercise price
- $6.57
- Footnotes
- F2, F4
NDRA
holding
Derivative
Warrants
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Oct 2026
- Ownership
- By LHE LNG Holdings LLC
- Underlying class
- Common Stock
- Underlying amount
- 1,156,774
- Exercise price
- $6.57
- Footnotes
- F2, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Represents 66,846 shares of common stock, par value $0.0001 per share (the "Common Stock"), of ENDRA Life Sciences Inc. (the "Issuer"), held by LHE LNG Holdings LLC ("LHE LNG"), a wholly owned subsidiary of ASP Isotopes Inc. (the "ASP Isotopes").
Footnote F2
Represents securities held by LHE LNG. ASP Isotopes controls LHE LNG and may be deemed to beneficially own securities of the Issuer held by LHE LNG. ASP Isotopes and LHE LNG each disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein. This report shall not be deemed an admission that ASP Isotopes or LHE LNG is the beneficial owner of such securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Footnote F3
Represents pre-funded warrants to purchase up to (i) 187,169 shares of Common Stock of the Issuer held by LHE LNG exercisable within 60 days of the date hereof and (ii) 324,372 shares of Common Stock of the Issuer held by LHE LNG exercisable on or after the date that the Issuer obtains stockholder approval of the issuance of the shares of Common Stock underlying the pre-funded warrants and warrants reported herein (the "Stockholder Approval"). The pre-funded warrants do not expire.
Footnote F4
Represents warrants to purchase an aggregate of up to 1,156,774 shares of Common Stock at an exercise price of $6.57 held by LHE LNG, which are not exercisable until Stockholder Approval is obtained. The warrants expire on May 27, 2031.